ERBB2 and breast carcinoma: In our large cohort of 547 breast cancer patients with paired samples of primary tumor and locoregional/distant metastases, HER2-low breast cancer accounted for almost a half of the entire HER2-negative cohort (45%), consistently with available evidence21.